Skip to main content
PMC home page
Immunology logoLink to Immunology
. 1978 Jan;34(1):29–40.

A new function of the activated third component of complement: binding to C5, an essential step for C5 activation

W Vogt, Gjsa Schmidt, Beate Von Buttlar, L Dieminger
PMCID: PMC1457321  PMID: 624565

Abstract

Incubation of factor B, factor [unk]D, (properdin) and C3b—or of C1[unk]s, C4b and C2—with C3 and/or C5 in a fluid system leads to the generation of C3 cleaving activity while C5 remains unaffected. C5 can be cleaved—activated—when in addition to the enzyme-generating components of either pathway C3b is present which has been fixed to a solid surface immediately after its release from C3 by a surface-fixed enzyme. This has been demonstrated with three C3b-carrying solids: agarose to which C3b was fixed after cleavage of C3 by agarose-coupled trypsin (Ag-C3b), zymosan incubated with human serum (Z-C3b) and sheep red cells in the state EAC43. C3b fixed to these surfaces after release in the fluid phase by soluble enzymes does in general not support C5 cleavage. C3b species active in C5 cleaving processes differ from those inactive by having a newly discovered property: active C3b is capable of reversibly binding C5. Fluid C3 convertase C3b[unk]B cleaves C5 in the presence of surface-fixed active C3b also under conditions under which it cannot interact with the latter. This indicates that two C3b molecules having different functions are involved in this system, one which is incorporated in the enzyme complex and another which binds and thereby prepares C5 for cleavage. The binding requires a special configuration of C3b which is preserved only by fixation immediately after its generation from C3. Efficient binding is possible only when C3b is free of other ligands such as factor B or properdin; these components interfere with binding and cleavage of C5 when having access to active C3b. C5 cleavage by the convertase of the classical complement pathway, C42, appears to proceed by the same mechanism, i.e. free C42 per se attacks C5 when this is bound to active C3b. It is concluded from the results that C5-cleaving complement enzymes do not differ in composition from C3 convertases. The active C3b which is essential for C5 cleavage, and existent only on surfaces, serves to modulate the substrate configuration to make it accessible to the enzyme.

Full text

PDF
29

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Daha M. R., Fearon D. T., Austen K. F. C3 requirements for formation of alternative pathway C5 convertase. J Immunol. 1976 Aug;117(2):630–634. [PubMed] [Google Scholar]
  2. Dias Da Silva W., Lepow I. H. Complement as a mediator of inflammation. II. Biological properties of anaphylatoxin prepared with purified components of human complement. J Exp Med. 1967 May 1;125(5):921–946. doi: 10.1084/jem.125.5.921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dieminger L., Vogt W., Lynen R. Purification and some properties of factor D of the human properdin system. Z Immunitatsforsch Immunobiol. 1976 Nov;152(3):231–243. [PubMed] [Google Scholar]
  4. Hammer C. H., Abramovitz A. S., Mayer M. M. A new activity of complement component C3: cell-bound C3b potentiates lysis of erythrocytes by C5b,6 and terminal components. J Immunol. 1976 Sep;117(3):830–834. [PubMed] [Google Scholar]
  5. Lynen R., Brade V., Wolf A., Vogt W. Purification and some properties of a heat labile serum factor (UP); identity with glycine-rich beta-glycoprotein and properdin factor B. Hoppe Seylers Z Physiol Chem. 1973 Jan;354(1):37–47. doi: 10.1515/bchm2.1973.354.1.37. [DOI] [PubMed] [Google Scholar]
  6. Medicus R. G., Götze O., Müller-Eberhard H. J. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. J Exp Med. 1976 Oct 1;144(4):1076–1093. doi: 10.1084/jem.144.4.1076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Molenaar J. L., Müller M. A., Engelfriet C. P., Pondman K. W. Changes in antigenic properties of human C3 upon activation and conversion by trypsin. J Immunol. 1974 Apr;112(4):1444–1451. [PubMed] [Google Scholar]
  8. Molenaar J. L., Müller M., Pondman K. W. A new preparative method for isolation of human C3 with affinity chromatography. J Immunol. 1973 Jun;110(6):1570–1574. [PubMed] [Google Scholar]
  9. Okada H., Okada N. Activated guinea-pig C3 and the immune adherence receptor (a complement receptor) on cell membranes. Immunology. 1975 Jun;28(6):1165–1171. [PMC free article] [PubMed] [Google Scholar]
  10. TODD E. W., PILLEMER L., LEPOW I. H. The properdin system and immunity. IX. Studies on the purification of human properdin. J Immunol. 1959 Oct;83:418–427. [PubMed] [Google Scholar]
  11. Vogt W., Dames W., Schmidt G., Dieminger L. Complement activation by the properdin system: formation of a stoichiometric. C3 cleaving complex of properdin factor B with C36. Immunochemistry. 1977 Mar;14(3):201–205. doi: 10.1016/0019-2791(77)90195-1. [DOI] [PubMed] [Google Scholar]
  12. Vogt W., Schmidt G., Dieminger L., Lynen R. Formation and composition of the C3 activating enzyme complex of the properdin system. Sequential assembly of its components on solid-phase trypsin-agarose. Z Immunitatsforsch Exp Klin Immunol. 1975 Jul;149(5):440–455. [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES